Greater Manchester Medicines Management Group

images courtesy of NHS Photo Library

NHS logo

News

<< Back

News Summary

From this page you will be able to access a summary of additions or changes to the GMMMG website during March 2020

March 2020

 

Pathways and Guidelines Development Subgroup (PaGDSG)

18.3.20

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, an updated Greater Manchester wide Shared Care Protocol for mycophenolate for interstitial lung disease is in development. We now seek the comments on this draft. This consultation period is open until 5pm on Wednesday 29th April 2020.

16.3.20

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, an new Greater Manchester wide Shared Care Protocol for Amiodarone for Severe Rhythm Disorder in Adults is in development. We now seek the comments on this draft. This consultation period is open until 5pm on Monday 27th  April 2020.

  • This SCP has been developed in response to NHSE guidance on medicines not to be routinely prescribed in primary care and subsequent update of the GMMMG RAG status to AMBER.
  • The SCP will support existing prescribing and monitoring of amiodarone across GM.
  • There are no service or commissioning implications associated with this SCP.

12.3.20

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, an updated Greater Manchester wide Shared Care Protocol for methotrexate for interstitial lung disease is in development. We now seek the comments on this draft. This consultation period is open until 5pm on Wednesday 22nd April 2020.

12.3.20

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester wide Shared Care Protocol for hydroxychloroquine for interstitial lung disease is in development. We now seek the comments on this draft. This consultation period is open until 5pm on Wednesday 22nd April 2020.

Formulary and Managed Entry Subgroup (FMESG)

19.3.20

Pending a safety review, the EMA has recommended that women taking ulipristal acetate for fibroids should stop treatment, and no new prescriptions should be started. Ulipristal has therefore been removed from formulary pending the outcome of this review. For more information please visit the EMA website or see the MHRA Drug Alert.

9.3.20

The following FMESG actions for February 2020 have been proposed. We now seek comments on these proposals.  This consultation is open until 5pm on Monday 20th April.

<< Back

Line

TERMS AND CONDITIONS    |    CONTACT US    |    ABOUT US    |    ARCHIVE

RSS Feed
 
spacer